自然化合物 - - 莱因和PROTAC释放出强大的VEGFR-2降解剂
Ziqing Zhang1, Meng Xu1, Ruling Shi2
1Engineering Research Centre of Molecular Medicine of Ministry of Education, Key Laboratory of Fujian Molecular Medicine, Key Laboratory of Precision Medicine and Molecular Diagnosis of Fujian Universities, Key Laboratory of Xiamen Marine and Gene Drugs, School of Medicine, Huaqiao University, 3622021, Quanzhou, P. R. China.
Chemistry & biodiversity
|May 31, 2024
概括
研究人员从菌中开发出了新的PROTAC,通过降解A549细胞中的VEGFR-2来显示强大的抗瘤活性. 这种以天然产品为基础的方法为开发向癌症治疗提供了一个新的策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 血管内皮生长因子受体2 (VEGFR-2) 是阻断瘤血管生成的关键标.
- 开发有效的针对VEGFR-2的抗瘤药物仍然是研究的关键领域.
研究的目的:
- 为了合成和优化使用天然产品rhein的新型蛋白质溶解向金马 (PROTACs).
- 评估这些新型PROTACs对VEGFR-2的抗瘤疗效和作用机制.
主要方法:
- 合成了15种不同的基于莱因的PROTAC分子.
- 使用A549细胞对抗瘤活性进行体外评估,包括IC50的确定.
- 调查VEGFR-2降解途径,包括时间依赖性,可逆性和蛋白质酶体的参与,无处不在和CRBN.
- 细胞周期分析和细胞亡测定.
- 分子对接模拟以评估与VEGFR-2的结合.
主要成果:
- 该PROTAC分子D9在A549细胞 (IC50=5.88μM) 中表现出显著的抗瘤疗效,其性能超过了rhein的15倍.
- D9有效诱导了VEGFR-2的时间依赖和可逆降解,依赖于蛋白酶体,无处不在和CRBN.
- 在A549细胞中,D9触发了亡和G1阶段细胞周期停止.
- 分子对接证实了D9具有结合VEGFR-2的潜力.
结论:
- 基于天然产品的PROTAC技术可用于开发新的VEGFR-2降解剂.
- D9是新一代向性抗癌药物的有前途的化合物.
- 这项研究为针对VEGFR-2的药理学药物提供了新的轨迹.
相关概念视频
01:10Mechanism of Angiogenesis
6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
01:16TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K